Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

OBJECTIVES: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. In China, sorafenib and oxaliplatin plus infusional-fluorouracil/leucovorin (FOLFOX4) are approved for the systemic treatment of advanced HCC. This study compared the cost-effectiveness of these therapie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cost Eff Resour Alloc
Main Authors: Qin, Shukui, Kruger, Eliza, Tan, Seng Chuen, Cheng, Shuqun, Wang, Nanya, Liang, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076412/
https://ncbi.nlm.nih.gov/pubmed/30087583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-018-0112-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados